IN2012DN00767A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00767A
IN2012DN00767A IN767DEN2012A IN2012DN00767A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A IN 767DEN2012 A IN767DEN2012 A IN 767DEN2012A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A
Authority
IN
India
Prior art keywords
therapy
initiation
tools
response
serum
Prior art date
Application number
Inventor
Visvanathan Sudha
Wagner Carrie
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IN2012DN00767A publication Critical patent/IN2012DN00767A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNEα agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin.
IN767DEN2012 2009-07-28 2010-07-12 IN2012DN00767A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22899409P 2009-07-28 2009-07-28
PCT/US2010/041714 WO2011014349A1 (en) 2009-07-28 2010-07-12 Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis

Publications (1)

Publication Number Publication Date
IN2012DN00767A true IN2012DN00767A (en) 2015-06-26

Family

ID=43529642

Family Applications (1)

Application Number Title Priority Date Filing Date
IN767DEN2012 IN2012DN00767A (en) 2009-07-28 2010-07-12

Country Status (7)

Country Link
US (1) US20120178100A1 (en)
EP (1) EP2460007A4 (en)
CN (1) CN102576015B (en)
AU (1) AU2010276665A1 (en)
CA (1) CA2769462A1 (en)
IN (1) IN2012DN00767A (en)
WO (1) WO2011014349A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2683419B1 (en) 2011-03-11 2018-05-09 Vib Vzw Molecules and methods for inhibition and detection of proteins
JP2015504430A (en) * 2011-11-21 2015-02-12 ノバルティス アーゲー Methods of treating psoriatic arthritis (PSA) using IL-7 antagonists and PSA-responsive or non-responsive alleles
FR3010188B1 (en) * 2013-09-05 2017-11-24 Univ Joseph Fourier - Grenoble 1 THERAGNOSTIC PROCESS FOR THE TREATMENT OF CHRONIC INFLAMMATORY RHUMATISMS
EP3356832A4 (en) * 2015-09-29 2019-06-19 Sasso, Eric Biomarkers and methods for assessing psoriatic arthritis disease activity
JP6751157B2 (en) * 2016-05-12 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ System for predicting the efficacy of targeted drugs to treat disease
CN109580759A (en) * 2017-09-28 2019-04-05 成都飞机工业（集团）有限责任公司 A kind of quadrupole mass spectrometer
US11232344B2 (en) 2017-10-31 2022-01-25 General Electric Company Multi-task feature selection neural networks
CA3127748A1 (en) * 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
CN114518416A (en) * 2020-11-20 2022-05-20 上海交通大学医学院附属瑞金医院 Marker for judging response and recurrence of psoriasis to IL-17A antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002230997A1 (en) * 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
KR101539684B1 (en) * 2010-05-14 2015-07-27 애브비 인코포레이티드 Il-1 binding proteins

Also Published As

Publication number Publication date
WO2011014349A1 (en) 2011-02-03
AU2010276665A1 (en) 2012-02-23
CA2769462A1 (en) 2011-02-03
CN102576015B (en) 2014-09-10
CN102576015A (en) 2012-07-11
US20120178100A1 (en) 2012-07-12
EP2460007A4 (en) 2013-06-19
EP2460007A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
IN2012DN00767A (en)
MX2018012580A (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia.
BR112014031365A2 (en) methods of detecting disease or conditions
BR112015025407A2 (en) method and device for testing a transformer
WO2008036835A3 (en) Methods and compositions for upregulation of peroxiredoxin activity
BR112013006528A2 (en) cancer phospholipidoma
EA201690213A1 (en) COMPOSITIONS AND METHOD FOR TREATMENT OF CONNECTED STATES
BR112015029852A2 (en) method for predicting or monitoring whether a patient suffering from cancer or an autoimmune disease will respond or respond to treatment with a tlr-9 agonist, tlr-9 agonist for use in a cancer treatment method, and a kit to predict or monitor if a patient suffering from cancer or autoimmune disease will respond or respond to treatment with a tlr-9 agonist
BR112018003300A2 (en) systems and methods for determining information related to a current order based on historical orders
BR112017005360A2 (en) methods for identifying a fertility status and for measuring a fertility status, and kit for identifying a fertility status.
BR112015004631A2 (en) genetic markers of mastitis resistance
BR112012024175A2 (en) hbf and a1m as early stage markers for preeclampsia
MX2014011045A (en) Method for selecting or identifying a subject for v1b antagonist therapy.
BR112013025287A2 (en) steroid receptor assays to detect tumor cells
BR112018075820A2 (en) method for inferring the activity of a transcription factor from a signal transduction pathway in an individual, method for assessing the suitability of a therapy for an individual, system for use in inferring the activity of a transcription factor for a transduction pathway signal in an individual, system for use in assessing the suitability of a therapy for an individual, and computer program
BR112021021574A2 (en) Method to identify a reproductive approach in an individual suffering from a varicocele
PL419784A1 (en) Application of metabolites as biomarkers to forecast premature delivery and method for forecasting premature delivery
UA108284U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
UA109274U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
UA108612U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
UA108263U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
UA108283U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
PL440701A1 (en) Panel of markers for predicting the occurrence of epilepsy relapses in patients with tuberous sclerosis, in vitro method for predicting the occurrence of epilepsy recurrence in patients with tuberous sclerosis and use of a panel of markers in this method
UA108259U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
UA82147U (en) Method for prediction of emergence risk of ischaemic stroke